Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer

BACKGROUND: Preclinical studies showed metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates programmed cell death protein-1 (PD-1) blockade. We hypothesized that metformin with nivolumab would elicit potent antitumor and immune modulatory activity in metastatic microsatelli...

Descripción completa

Detalles Bibliográficos
Autores principales: Akce, Mehmet, Farran, Batoul, Switchenko, Jeffrey M, Rupji, Manali, Kang, Sandra, Khalil, Lana, Ruggieri-Joyce, Amanda, Olson, Brian, Shaib, Walid L, Wu, Christina, Alese, Olatunji B, Diab, Maria, Lesinski, Gregory B, El-Rayes, Bassel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603338/
https://www.ncbi.nlm.nih.gov/pubmed/37852737
http://dx.doi.org/10.1136/jitc-2023-007235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603338/
https://www.ncbi.nlm.nih.gov/pubmed/37852737
http://dx.doi.org/10.1136/jitc-2023-007235

Ejemplares similares